A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Clinical trial NCT01484275 · COMPLETED
Trial details
- NCT number
- NCT01484275
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-03-01
- Primary completion
- 2015-05-12
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.